Are the PD-1/PD-L1 Immune Checkpoint Inhibitors Completely Interchangeable in Lung Cancer Management? (BMIC-015)

13/11/2017 6 min
Are the PD-1/PD-L1 Immune Checkpoint Inhibitors Completely Interchangeable in Lung Cancer Management? (BMIC-015)

Listen "Are the PD-1/PD-L1 Immune Checkpoint Inhibitors Completely Interchangeable in Lung Cancer Management? (BMIC-015)"

Episode Synopsis

Dr. Jack West addresses the question of whether the data with various PD-1 and PD-L1 inhibitors in lung cancer management can be viewed as a class effect and whether these immune checkpoint inhibitors should be considered interchangeable.

More episodes of the podcast The Beacon (Audio)